Stay updated on Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added a Locations section featuring New York as a study location. Page revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T21:04:52.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    The Publications section now states that entries are automatically filled from PubMed and may not be about the study, with revision updated to v3.3.2. The older PubMed description and revision v3.2.0 were removed.
    Difference
    0.1%
    Check dated 2025-11-25T10:47:44.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Removed the site-wide notice about government funding delays; no study content or core details (such as eligibility, outcomes, or locations) are affected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-18T06:55:35.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    The screenshots show only minor formatting/layout adjustments with no changes to core study details such as objectives, eligibility criteria, interventions, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T21:07:54.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    Key updates: version bump to v3.2.0 and the addition of an up-to-date operating status notice (including NIH Clinical Center status and links). Deletion of the previous version tag v3.1.0. overall, indicates a maintenance refresh with updated operating status information.
    Difference
    2%
    Check dated 2025-10-06T05:36:45.000Z thumbnail image
  9. Check
    100 days ago
    Change Detected
    Summary
    - Added new page revision tag: v3.1.0. - Removed several cancer-related topic terms (e.g., Neoplasms by Histologic Type, Carcinoma, Carcinoma, Ovarian Epithelial) and an older revision tag v3.0.2, indicating pruning of topics and a version update.
    Difference
    0.5%
    Check dated 2025-09-29T03:07:27.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.